These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11240449)

  • 1. Rare side-effects of fenofibrate.
    Rabasa-Lhoret R; Rasamisoa M; Avignon A; Monnier L
    Diabetes Metab; 2001 Feb; 27(1):66-8. PubMed ID: 11240449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate-induced myopathy.
    Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
    Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gynecomastia associated with fenofibrate.
    Gardette V; Vezzosi D; Maiza JC; Montastruc JL; Olivier P
    Ann Pharmacother; 2007 Mar; 41(3):508-10. PubMed ID: 17341535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Septic-toxic shock due to rhabdomyolysis in a patient treated with fenofibrate].
    Duda-Król W; Jórasz I; Dabrowska M; Polubiec A; Kusz-Rynkun A
    Wiad Lek; 2000; 53(7-8):454-7. PubMed ID: 11070769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J; Ye P
    Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Necrotizing myopathy with antilipemic agents. Case report and review of the literature].
    Berger O; Zifko U; Jellinger K; Machacek E; Grisold W
    Nervenarzt; 1993 Aug; 64(8):539-44. PubMed ID: 8413753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Muscular toxicity due to fenofibrate. Apropos of a case].
    Giraud P; Cassou M; Paul R; Guidet M
    Rev Rhum Mal Osteoartic; 1982 Feb; 49(2):162. PubMed ID: 7063798
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hypothyroidism and muscular toxicity from fenofibrate, report of a case revealed by polymyositis].
    Cherif O; Karma F; Ben Amor G; Kochbati S; Ben Amor B; Rokbani L
    Tunis Med; 1997 Feb; 75(2):87-91. PubMed ID: 9506029
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting vascular risk in patients with metabolic syndrome but without diabetes.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Didangelos TP; Peletidou A; Kleta D; Karagiannis A; Kakafika AI; Tziomalos K; Elisaf M
    Metabolism; 2005 Aug; 54(8):1065-74. PubMed ID: 16092057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
    Jones PH; Davidson MH
    Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
    Magee G; Sharpe PC
    J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
    Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.
    Tahmaz M; Kumbasar B; Ergen K; Ure U; Karatemiz G; Kazancioglu R
    Ren Fail; 2007; 29(7):927-30. PubMed ID: 17994463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
    J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
    Melenovsky V; Stulc T; Kozich V; Grauova B; Krijt J; Wichterle D; Haas T; Malik J; Hradec J; Ceska R
    Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
    Chatley P; Badyal DK; Calton R; Khosla PP
    Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):217-21. PubMed ID: 17520105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis.
    Lee JY; Medellin MV; Tumpkin C
    South Med J; 2000 Aug; 93(8):807-8. PubMed ID: 10963515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
    Dierkes J; Westphal S; Luley C
    Expert Opin Drug Saf; 2004 Mar; 3(2):101-11. PubMed ID: 15006716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.